Safe disposal of prescription drugs is turning out to be a costly endeavor, and the pharmaceutical industry seems to want no part of it.
Safe disposal of prescription drugs is turning out to be a costly endeavor, and the pharmaceutical industry seems to want no part of it.
The National Take-Back Initiative, a biannual event coordinated by the Drug Enforcement Administration (DEA), was launched in September 2010—a venture meant to allow the safe disposal of prescription medications and avoid misuse as well as unwanted environmental effects—a danger associated with flushing these medications into the water streams. Since then, the DEA has been working with the Congress to install more permanent regulations, such as the Safe and Secure Drug Disposal Act of 2010.
But drug disposal costs money, costs that pharmaceutical manufactures do not want to bear. Local governments—such as Alameda County and the city of San Francisco—have taken the initiative to pass ordinance that requires drug manufacturers who have at least 1 prescription medication or over-the-counter (OTC) medicines for sale in their city or county, to participate in stewardship programs for safe disposal. According to STAT, Alameda County estimated the annual costs at $330,000, while the trade group PhRMA estimated the costs could cross $1 million.
STAT reports that the industry has now brought lobbying to the local level, after the US Supreme Court overruled their objections. A national trade association that represents manufacturers of OTC medications and dietary supplements, started calling residents of Los Angeles County warning them of a tax hike due to the take-back program. Another approach is forcing the local governments to implement a state-run and funded program for the collection and disposal of hazardous waste.
One such bill (Assembly Bill 45), introduced in the California state assembly, was amended in January this year to reflect the changes. Some of the trade groups have proposed to fund a nonprofit organization at $1 million annually over a 5-year period, to educate consumers in California on appropriate handling and disposal of drugs. This is only if local governments commit to managing and funding the actual disposal.
Meanwhile, As You Sow, a nonprofit, recently sent a letter on behalf of 22 investment firms addressing the CEOs of 10 major pharmaceutical companies, to provide shareholders with a policy statement on the take back program. “We hope you will work with industry peers to develop policies leading to a national drug take back program, and provide primary financial responsibility for the program. We believe it’s time for the industry to manage the end of life portion of the product life cycle in the same manner that it manages design and marketing of its goods and services,” the letter states.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More